Biological therapies for myasthenia gravis-Reference-Cited by-同舟云学术

Biological therapies for myasthenia gravis

Published:2023-02-28 Issue:3 Volume:23 Page:253-260
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Uzawa Akiyuki¹,Utsugisawa Kimiaki²

Affiliation:

1. Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan

2. Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan

Funder

Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour, and Welfare of Japan

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2184257

Reference40 articles.

1. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

2. Myasthenia gravis: past, present, and future

3. Antibodies against Muscle-Specific Kinase Impair Both Presynaptic and Postsynaptic Functions in a Murine Model of Myasthenia Gravis

4. Early fast‐acting treatment strategy against generalized myasthenia gravis

5. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis;Frontiers in Immunology;2024-06-06

2. Innovationen in der Myasthenietherapie: eine Bestandsaufnahme;DGNeurologie;2024-02-19

3. Usefulness and analytical performances of complement multiplex assay for measuring complement biomarkers in plasma;Clinica Chimica Acta;2024-02

4. Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov;Scientific Reports;2024-01-24

5. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy;European Journal of Neurology;2023-12-20